Researchers at the Francis Crick Institute in the UK have shed light on how cancer cells survive after being cut off from oxygen, a finding that could help to prevent cancer from becoming resistant to treatment. When oxygen supplies are low, most cells change which proteins… Read More
Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). The study is evaluating PT-112 in patients who have been treated with at least three prior life-prolonging therapies… Read More
The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the most common… Read More
Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More
Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs constitute a promising approach for treating cervical cancer, though rejection by the host’s immune system is a major hurdle. In a recent… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. After assessing its novel chemical and biological properties, including an attractive non-clinical safety and efficacy profile, the FDA has granted Orphan Drug Status, conferring… Read More
Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This discovery was made by using artificial intelligence (AI) to help unlock new discoveries about the evolution of prostate cancer and could lead to the… Read More
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More
CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. The study shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with… Read More
The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More
Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society1 state that “a little over… Read More
DDW Editor Reece Armstrong speaks to Ron Alfa, CEO & Co-founder at NOETIK, about the company’s mission to utilise artificial intelligence (AI) and spatial biology to develop better immunotherapies for cancer patients. Reece A: What are some of the human limitations to current drug discovery research for immunotherapies? Ron A:… Read More
CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology making… Read More
A drug derived from oleic acid – which naturally occurs in animal and vegetable fats such as olive oil – has shown promise for patients with brain cancer, following a study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK. Results… Read More
DDW recently hosted an online event, sponsored by Taconic Biosciences, which outlined areas of advancement and opportunity in the cancer research market. Megan Thomas summarises the key points examined by the participating experts. New drug discovery and development concepts The event started with a panel discussion on new drug discovery… Read More
Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More
